http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Veracyte Announces Second Quarter 2018 Financial Results
-
Veracyte to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results on Monday, July 23, 2018
-
Veracyte Chairman and CEO to Speak at MedCity CONVERGE
-
Veracyte Named a San Francisco Bay Area “Top Workplace” for Fifth Consecutive Year
-
Veracyte to Present at the William Blair 38th Annual Growth Stock Conference
-
Veracyte (VCYT) Says New Study Published in JAMA Surgery Demonstrates Afirma GSC's Ability to Significantly Reduce Unnecessary Surgeries in Thyroid Cancer Diagnosis
-
Veracyte Announces New Study Published in JAMA Surgery Demonstrates Afirma GSC’s Ability to Significantly Reduce Unnecessary Surgeries in Thyroid Cancer Diagnosis
-
Veracyte (VCYT) Reports Data from Multiple Studies Demonstrate 'Real-World' Value of Afirma Genomic Sequencing Classifier in Thyroid Cancer Diagnosis
-
Veracyte Announces That Data From Multiple Studies Demonstrate “Real-World” Value of Afirma Genomic Sequencing Classifier in Thyroid Cancer Diagnosis
-
Veracyte Launches Early Access Program for Envisia Genomic Classifier to Improve Diagnosis of IPF
-
Veracyte Announces Launch of New Afirma Xpression Atlas at 2018 AACE Congress
-
Veracyte to Launch New Afirma Xpression Atlas and Present Platform Performance Data at AACE 2018 Meeting
-
**UPDATED WITH NEW TIME**: Veracyte to Present at the 2018 UBS Global Healthcare Conference
-
Veracyte to Present at the 2018 UBS Global Healthcare Conference
-
Veracyte Announces First Quarter 2018 Financial Results
-
Veracyte to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results on Tuesday, May 1, 2018
-
Veracyte (VCYT) Announces Research Collaboration With Loxo Oncology for Precision Medicine
-
Veracyte Announces Precision Medicine Collaboration With Loxo Oncology
-
Veracyte Unveils Afirma Xpression Atlas Platform at ENDO 2018
-
Veracyte Announces New Data Suggesting Afirma GSC’s Ability to Help Significantly More Patients Avoid Unnecessary Thyroid Surgery
-
Veracyte (VCYT) Says New Data Demonstrating Real-World Performance of Afirma GSC to Be Presented at ENDO
-
Veracyte Announces New Data Demonstrating “Real-World” Performance of Afirma GSC To Be Presented at ENDO 2018
-
Veracyte Announces Fourth Quarter and Full-Year 2017 Financial Results, Provides 2018 Financial Outlook
-
Veracyte to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2017 Financial Results on Tuesday, February 27, 2018
-
Veracyte to Present at LEERINK Partners 7th Annual Global Healthcare Conference
-
Veracyte Announces 100,000th Afirma Test Performed to Reduce Unnecessary Surgeries in Thyroid Cancer Diagnosis
-
Veracyte’s Chief Science and Medical Officer to Present at The Precision Medicine World Conference
-
Veracyte (VCYT) Reports Publication of Results from Patient Survey on Challenges in Diagnosing Interstitial Lung Disease
-
Veracyte Announces Publication of Results from Patient Survey Quantifying the Challenges in Diagnosing Interstitial Lung Disease
-
Veracyte (VCYT) Announces Strategic Realignment, Reiterates Rev. Guidance
-
Veracyte Announces Strategic Realignment and New Appointments to Advance Commercial Growth
-
Veracyte (VCYT) Reports Publication of Data Confirming Analytical Validity of Envisia Genomic Classifier for Use in IPF Diagnosis
-
Veracyte Announces Publication of Data Confirming Analytical Validity of Envisia Genomic Classifier for Use in IPF Diagnosis
-
Veracyte to Present at the Piper Jaffray 29th Annual Healthcare Conference
-
Veracyte (VCYT) Says New Data Suggests Envisia Genomic Classifier Enables as Confident a Diagnosis in IPF as Surgical Pathology
-
Veracyte Announces New Clinical Utility Data Suggesting Envisia Genomic Classifier Enables as Confident a Diagnosis in IPF as Surgical Pathology
-
Veracyte Announces Third Quarter 2017 Financial Results
-
CORRECTING and REPLACING Veracyte Announces Presentation of New Clinical Utility Data at CHEST 2017 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer Diagnosis
-
Veracyte to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum
-
Veracyte Announces Presentation of New Clinical Utility Data at CHEST 2017 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer Diagnosis
-
Veracyte to Host Conference Call and Webcast to Discuss Third Quarter 2017 Financial Results on Monday, November 6, 2017
-
Veracyte (VCYT) Reports New Data Highlighting Performance of the Afirma GSC Ensemble Machine Learning Algorithms in Challenging Thyroid Cancer Subtypes
-
Veracyte Announces New Data Highlighting Performance of the Afirma GSC Ensemble Machine Learning Algorithms in Challenging Thyroid Cancer Subtypes to Be Presented at ATA
-
Veracyte Announces Presentation of New Data Validating Accuracy of BRAF V600E and Parathyroid Tissue Classifiers at ATA Annual Meeting
-
Veracyte (VCYT) Announces New Data Demonstrating Clinical Utility of Percepta Bronchial Genomic Classifier to be Presented at CHEST
-
Veracyte Announces New Data Demonstrating Clinical Utility of Percepta Bronchial Genomic Classifier to be Presented at CHEST Annual Meeting 2017
-
Veracyte Chairman and CEO Bonnie Anderson Receives Prestigious Innovation Award at Biomedical Engineering Society Annual Meeting
-
Veracyte Announces Data From Five Studies Validating the Next-Generation Afirma Genomic Sequencing Classifier to Be Presented at ATA 2017 Annual Meeting
-
Veracyte Announces Release of 2018 Preliminary Reimbursement Rate for Afirma Genomic Classifier Under PAMA
-
Awareness Campaign Takes Lung Cancer Risk Head-On, Asking North Carolinians To Screen Together

